Temporal, Age, and Racial and Ethnic Trends in Allergen Consumption from 2-Day 24-Hour Recalls, NHANES 2003-2023

Allergic Diseases

Organic Food Consumption Might Protect Against Sensitisation to Inhalant Allergens at School Age: The PARIS Cohort

Allergy

Pernin-Schneider M, Amazouz H, Lezmi G, Bourgoin-Heck M, Just J, Momas I, Rancière F

doi: 10.1111/all.16433

Allergic Diseases

The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

Contact Dermatitis

Caroppo ES, Casciola G, Hansel K, Guglielmo A, Ferrucci SM, Guarneri F, Lauriola MM, Napolitano M, Patruno C, Romita P, Schena D, Trave I, Bianchi L, Stingeni L, 2‐HEMA Study Group

doi: 10.1111/cod.14800

Allergic Diseases

Trends in Contact Allergy to Preservatives From 2014 to 2023: Benzisothiazolinone on the Rise

Contact Dermatitis

Søgaard R, Kursawe Larsen C, Johansen JD, Schwensen JFB

doi: 10.1111/cod.14818

Rheumatoid Arthritis

Risk and temporal trends of heart failure subtypes in rheumatoid arthritis

Semin Arthritis Rheum

Johnson TM, Yang Y, Roul P, Frideres H, Baker JF, Sauer BC, Cannon GW, Kunkel GA, Bookani KR, Mikuls TR, England BR

doi: 10.1016/j.semarthrit.2025.152816

Systemic Lupus Erythematosus

Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden

Rheumatology (Oxford)

Dominicus A, Mageau A, Nguyen NV, Blomkvist Sporre K, Svenungsson E, Arkema EV

doi: 10.1093/rheumatology/keaf192

Allergic Diseases

Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023

Contact Dermatitis

Pesqué D, Planella-Fontanillas N, Borrego L, Sanz-Sánchez T, Zaragoza-Ninet V, Serra-Baldrich E, Miquel-Miquel FJ, Silvestre-Salvador JF, Córdoba-Guijarro S, Sánchez-Gilo A, Mercader-García P, Navarro-Triviño FJ, Ortiz-de-Frutos FJ, Tous-Romero F, Rodríguez-Serna M, Melé-Ninot G, Barrabés-Torrella C, Ruiz-González I, Pastor-Nieto MA, Carrascosa-Carrillo JM, Gómez-de-la-Fuente E, Sánchez-Pedreño-Guillén P, Sánchez-Pérez J, Pereyra-Rodríguez JJ, Gatica-Ortega ME, González-Pérez R, Pujol RM, Descalzo MÁG, García-Doval I, Giménez-Arnau AM

doi: 10.1111/cod.14702

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Rheumatoid Arthritis

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Arthritis Res Ther

Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Rezk MF, Zeng X

doi: 10.1186/s13075-024-03375-w

Rheumatoid Arthritis

A cohort study on the associations between age at natural menopause and rheumatoid arthritis in postmenopausal women from the Canadian Longitudinal Study on Aging

Semin Arthritis Rheum

Kesibi D, Rotondi M, Edgell H, Tamim H

doi: 10.1016/j.semarthrit.2025.152747

Related content

Organic Food Consumption Might Protect Against Sensitisation to Inhalant Allergens at School Age: The PARIS Cohort

The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

Trends in Contact Allergy to Preservatives From 2014 to 2023: Benzisothiazolinone on the Rise

Risk and temporal trends of heart failure subtypes in rheumatoid arthritis

Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden

Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

A cohort study on the associations between age at natural menopause and rheumatoid arthritis in postmenopausal women from the Canadian Longitudinal Study on Aging